期刊
JOURNAL OF CELLULAR PHYSIOLOGY
卷 234, 期 5, 页码 7645-7658出版社
WILEY
DOI: 10.1002/jcp.27526
关键词
inflammatory bone destruction; interleukin-37; lipopolysaccharide; nuclear factor-kappa B signaling; osteoclast differentiation
资金
- Special Funds for Social Undertaking and Livelihood Security Projects of Chongqing [CSTC2016SHMSZX130068]
- Youth development program of medical technology of PLA [16QNP103]
- Medical Research Funding of PLA of China [AWS14C003]
- Scientific and Medical Research Project of Chongqing, China [2018ZDXM030]
Excessive osteoclast formation is one of the important pathological features of inflammatory bone destruction. Interleukin-37 (IL-37) is an anti-inflammatory agent that is present throughout the body, but it displays low physiological retention. In our study, high levels of the IL-37 protein were detected in clinical specimens from patients with bone infections. However, the impact of IL-37 on osteoclast formation remains unclear. Next, IL-37 alleviated the inflammatory bone destruction in the mouse in vivo. We used receptor activator of nuclear factor-kappa B ligand and lipopolysaccharide to trigger osteoclastogenesis under physiological and pathological conditions to observe the role of IL-37 in this process and explore the potential mechanism of this phenomenon. In both induction models, IL-37 exerted inhibitory effects on osteoclast differentiation and bone resorption. Furthermore, IL-37 decreased the phosphorylation of inhibitor of kappa B alpha and p65 and the expression of nuclear factor of activated T cells c1, while the dimerization inhibitor of myeloid differentiation factor 88 reversed the effects. These data provide evidence that IL-37 modulates osteoclastogenesis and a theoretical basis for the clinical application of IL-37 as a treatment for bone loss-related diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据